Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus MIRAPEX ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus MIRAPEX ER.
CYCLOSET vs MIRAPEX ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Non-ergot dopamine agonist with high affinity for D2 and D3 receptor subtypes; stimulates dopamine receptors in the striatum.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Oral, start 0.375 mg once daily, titrate weekly by 0.375 mg/dose to 1.5 mg once daily (immediate-release); ER: same total daily dose once daily.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life: 8–12 hours in young healthy adults; prolonged to 16–40 hours in elderly (≥65 years) and up to 30 hours in moderate renal impairment (CrCl 20–50 mL/min).
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Renal excretion of unchanged drug and metabolites: ~90% in urine (pramipexole: ~70% unchanged; N-desmethyl metabolite: ~20%). Fecal excretion: ~2%. Biliary elimination: minimal.
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist